Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years

Summary

The purpose of the study is to better and systematically collect clinical data on the treatment of ibrutinib combined with R-CHOP/DHAP regimen for more scientific and accurate evaluation, our center has carried out the R-CHOP/R-DHAP alternative regimen combined with ibrutinib at age ≤ An observational clinical study on the safety and effectiveness of 65-year-old mantle cell lymphoma. Through this study, young mantle cell lymphomas in the Chinese population can be collected. Ibrutinib combined with R-CHOP/R-DHAP is used in the initial treatment. 2 and 6 cycles of ORR were used to evaluate survival indicators, and collect adverse reactions during treatment and recurrence rate after treatment.

Conditions

• Mantle Cell Lymphoma

Sponsors & Collaborators

• The Second Affiliated Hospital of Dalian Medical University

  collaborator OTHER

• Peking University First Hospital

  collaborator OTHER

• Beijing Hospital

  collaborator OTHER_GOV

• Beijing Tsinghua Changgeng Hospital

  collaborator OTHER

• China-Japan Friendship Hospital

  collaborator OTHER

• Chinese PLA General Hospital

  collaborator OTHER

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• Baotou Cancer Hospital

  collaborator OTHER

• Beijing Shijitan Hospital, Capital Medical University

  collaborator OTHER

• Shanxi Province Cancer Hospital

  collaborator OTHER

• Beijing Naval General Hospital

  collaborator OTHER

• First Hospital of China Medical University

  collaborator OTHER

• Jilin Provincial Tumor Hospital

  collaborator OTHER

• Shengjing Hospital

  collaborator OTHER

• 307 Hospital of PLA

  collaborator OTHER

• Peking Union Medical College Hospital

  collaborator OTHER

• Harbin Medical University

  collaborator OTHER

• Beijing Tongren Hospital

  collaborator OTHER

• Peking University Third Hospital

  lead OTHER

Principal Investigators

• Hongmei Jing, Professor · Peking University Third Hospital

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-12-30

Primary Completion

2023-12-30

Completion

2024-06-30

Countries

• China

Study Locations